Becton, Dickinson(US:BDX) Yahoo Finance·2025-10-23 09:17Company Overview - Becton, Dickinson and Company (BDX) is valued at $52.3 billion and is a leading medical technology company based in Franklin Lakes, New Jersey, founded in 1897. The company develops, manufactures, and sells a variety of medical devices, laboratory equipment, and diagnostic products aimed at improving healthcare safety, efficiency, and quality worldwide [1]. Earnings Expectations - BDX is expected to announce its fiscal fourth-quarter earnings for 2025 on November 6, with analysts predicting a profit of $3.91 per share on a diluted basis, which represents a 2.6% decrease from $3.81 per share in the same quarter last year. The company has a track record of exceeding Wall Street's EPS estimates in the last four quarters [2]. - For the full fiscal year, analysts anticipate BDX will report an EPS of $14.40, reflecting a 9.6% increase from $13.14 in fiscal 2024. EPS is projected to rise by 2.7% year over year to $14.79 in fiscal 2026 [3]. Stock Performance - Over the past year, BDX stock has declined by 21.5%, underperforming the S&P 500 Index, which gained 14.5%, and the Health Care Select Sector SPDR Fund, which saw a 3.4% dip [4]. - On October 17, BDX shares increased by 2.1%, outperforming several competitors in the medical technology sector, following Piper Sandler analyst Jason Bednar's reaffirmation of a "Hold" rating with a $200 price target [5]. Analyst Ratings - The consensus opinion among analysts on BDX stock is moderately bullish, with an overall "Moderate Buy" rating. Out of 17 analysts, six recommend a "Strong Buy," one suggests a "Moderate Buy," and ten give a "Hold." The average analyst price target for BDX is $216.23, indicating a potential upside of 14.9% from current levels [6].